Citius Oncology closes $9 million public offering

Citius Oncology Inc. (NASDAQ: CTOR) completed a public offering of 6,818,182 shares of common stock and warrants, generating gross proceeds of approximately $9 million before fees and expenses.

The company priced the offering at $1.32 per share. The warrants carry an exercise price of $1.32 per share, are immediately exercisable, and expire five years from issuance. Maxim Group LLC served as sole placement agent for the transaction.

Citius Oncology plans to use the net proceeds primarily to support commercialization of LYMPHIR, including milestone, royalty, or other payments under existing license agreements, as well as for working capital and general corporate purposes.

The securities were offered under a registration statement on Form S-1 filed with the Securities and Exchange Commission on July 14, 2025, and declared effective on July 16, 2025.

Citius Oncology is a majority-owned subsidiary of Citius Pharmaceuticals Inc. (NASDAQ: CTXR). The company received FDA approval for LYMPHIR in August 2024 for treating adults with relapsed or refractory cutaneous T-cell lymphoma who had at least one prior systemic therapy.

You May Also Be Interested In